United States
Print page content Print
Increase text size Decrease text size
Text Size
Cytopoint logo
The first monoclonal antibody therapy for canine atopic dermatitis

CYTOPOINT™ mimics the dog’s natural immune function; it targets the IL-31 pathway, which is involved in the cycle of itch and inflammation2

  • CYTOPOINT is a monoclonal antibody (mAb)* that specifically targets and neutralizes canine IL-31, an important cytokine involved in sending the itch signal to the brain in atopic dermatitis2

  • Because it is highly targeted to a specific cytokine involved in canine atopic dermatitis, CYTOPOINT has minimal impact on normal immune functions3

  • CYTOPOINT is eliminated via normal protein degradation pathways in the same way as naturally occurring antibodies§; metabolism does not involve the liver or kidneys

* Monoclonal antibody (mAb): a single, homogenous antibody preparation cloned from a single lineage of B cells. mAb therapy is designed to mimic a normal immune function by recognizing and binding to one single segment, or epitope, on a particular target antigen.4,5

Interleukin 31 (IL-31): a cytokine that triggers the process of sending itch signals to the brain. cIL-31 is canine IL-31.4,5

Cytokine: a protein that signals other cells by binding to receptors on those cells.4,5

§ mAbs are catabolized within cells into amino acids and peptides. They are not metabolized in the liver or kidneys, converted into reactive or toxic metabolites, or excreted in urine. Thus, they are highly unlikely to induce liver or kidney toxicity.4,5

Indication: CYTOPOINT aids in the reduction of clinical signs associated with atopic dermatitis in dogs.

References: 1. Data on file, Press Release, August 2015, Zoetis LLC. 2. Gonzales AJ, Humphrey WR, Messamore JE, et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol. 2013;24(1):48-53. doi:10.1111/j.1365-3164.2012.01098.x. 3. Data on file, Study Report No. C961R-US-13-051, Zoetis LLC. 4. Greenfield EA. Generating monoclonal antibodies. In: Greenfield EA, ed. Antibodies: A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2014:201-221. 5. Olivry T, Bainbridge G. Clinician’s Brief. Advances in veterinary medicine: therapeutic monoclonal antibodies for companion animals. March 2015. http://www.cliniciansbrief.com/sites/default/files/attachments/ZoetisCN_Mar_FNL.pdf.
Accessed June 21, 2016.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
Zoetis Services LLC. All rights reserved. CYT-00090